Literature DB >> 4426721

Peptichemio in the therapy of malignancies (phase-I-study). The evaluation committee.

N Gingold, E Pittermann, A Stacher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4426721

Source DB:  PubMed          Journal:  Int J Clin Pharmacol        ISSN： 0300-9718


× No keyword cloud information.
  5 in total

1.  Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil.

Authors:  R W Gasser; F Schmalzl
Journal:  Blut       Date:  1981-11

2.  Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

Authors:  M J Yagi; J G Bekesi; M D Daniel; J F Holland; A De Barbieri
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Authors:  M J Yagi; M Zanjani; J F Holland; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  R Larsson; S Dhar; H Ehrsson; P Nygren; R Lewensohn
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.